137 related articles for article (PubMed ID: 15533599)
1. The cancer recognition (CARE) antibody test.
Thornthwaite JT; McDuffee EC; Harris RB; Secor McVoy JR; Lane IW
Cancer Lett; 2004 Dec; 216(2):227-41. PubMed ID: 15533599
[TBL] [Abstract][Full Text] [Related]
2. Prognostic significance of circulating antibodies against carcinoembryonic antigen (anti-CEA) in patients with colon cancer.
Albanopoulos K; Armakolas A; Konstadoulakis MM; Leandros E; Tsiompanou E; Katsaragakis S; Alexiou D; Androulakis G
Am J Gastroenterol; 2000 Apr; 95(4):1056-61. PubMed ID: 10763959
[TBL] [Abstract][Full Text] [Related]
3. Anti-DNA topoisomerase II alpha autoantibodies in Japanese patients with systemic sclerosis.
Hayakawa I; Hasegawa M; Takehara K; Sato S
Arch Dermatol Res; 2005 Oct; 297(4):180-3. PubMed ID: 16180014
[TBL] [Abstract][Full Text] [Related]
4. The relation of serum anti-(GalNAc beta) and -para-Forssman disaccharide IgG levels to the progression and histological grading of gastrointestinal cancer.
Smorodin EP; Kurtenkov OA; Sergeyev BL; Chuzmarov VI; Afanasyev VP
Exp Oncol; 2007 Mar; 29(1):61-6. PubMed ID: 17431391
[TBL] [Abstract][Full Text] [Related]
5. Autoimmune response to anti-apoptotic protein survivin and its association with antibodies to p53 and c-myc in cancer detection.
Megliorino R; Shi FD; Peng XX; Wang X; Chan EK; Tan EM; Zhang JY
Cancer Detect Prev; 2005; 29(3):241-8. PubMed ID: 15896923
[TBL] [Abstract][Full Text] [Related]
6. The detection of quantitative serum p53 protein in lung cancer.
Sen E; Gönüllü U; Akar N
Tuberk Toraks; 2005; 53(3):231-7. PubMed ID: 16258881
[TBL] [Abstract][Full Text] [Related]
7. The pretreatment plasma level and diagnostic utility of M-CSF in benign breast tumor and breast cancer patients.
Ławicki S; Szmitkowski M; Wojtukiewicz M
Clin Chim Acta; 2006 Sep; 371(1-2):112-6. PubMed ID: 16631152
[TBL] [Abstract][Full Text] [Related]
8. Serum TIMP-1 in gastric cancer patients: a potential prognostic biomarker.
Wang CS; Wu TL; Tsao KC; Sun CF
Ann Clin Lab Sci; 2006; 36(1):23-30. PubMed ID: 16501233
[TBL] [Abstract][Full Text] [Related]
9. Characterization of BRCAA1 and its novel antigen epitope identification.
Cui D; Jin G; Gao T; Sun T; Tian F; Estrada GG; Gao H; Sarai A
Cancer Epidemiol Biomarkers Prev; 2004 Jul; 13(7):1136-45. PubMed ID: 15247124
[TBL] [Abstract][Full Text] [Related]
10. [A dynamic observation on serum cytokine and immunoglobulin (IgG, IgA, IgM) in patients with esophageal cancer].
Tang RG; Yuan XH; Tang TT; Tang XQ; Hang YQ; Qin HJ; Chen HM; Fang WZ; Long XK
Zhonghua Yu Fang Yi Xue Za Zhi; 2007 Jun; 41 Suppl():35-8. PubMed ID: 17767855
[TBL] [Abstract][Full Text] [Related]
11. Afamin and apolipoprotein A-IV: novel protein markers for ovarian cancer.
Dieplinger H; Ankerst DP; Burges A; Lenhard M; Lingenhel A; Fineder L; Buchner H; Stieber P
Cancer Epidemiol Biomarkers Prev; 2009 Apr; 18(4):1127-33. PubMed ID: 19336561
[TBL] [Abstract][Full Text] [Related]
12. Clinical significance of plasma level of vascular endothelial growth factor-C in patients with colorectal cancer.
Miyazaki T; Okada N; Ishibashi K; Ogata K; Ohsawa T; Ishiguro T; Nakada H; Yokoyama M; Matsuki M; Kato H; Kuwano H; Ishida H
Jpn J Clin Oncol; 2008 Dec; 38(12):839-43. PubMed ID: 18923001
[TBL] [Abstract][Full Text] [Related]
13. Detection of prostate cancer with a blood-based assay for early prostate cancer antigen.
Paul B; Dhir R; Landsittel D; Hitchens MR; Getzenberg RH
Cancer Res; 2005 May; 65(10):4097-100. PubMed ID: 15899799
[TBL] [Abstract][Full Text] [Related]
14. Soluble CD44 standard, CD44 variant 5 and CD44 variant 6 and their relation to staging in head and neck cancer.
Kawano T; Yanoma S; Nakamura Y; Ozeki A; Kokatsu T; Kubota A; Furukawa M; Tsukuda M
Acta Otolaryngol; 2005 Apr; 125(4):392-7. PubMed ID: 15823810
[TBL] [Abstract][Full Text] [Related]
15. Serum interleukin-12 levels in patients with gastric cancer.
Murakami S; Okubo K; Tsuji Y; Sakata H; Hamada S; Hirayama R
Surg Today; 2004; 34(12):1014-9. PubMed ID: 15580384
[TBL] [Abstract][Full Text] [Related]
16. Titration of serum p53 antibodies in 1,085 patients with various types of malignant tumors: a multiinstitutional analysis by the Japan p53 Antibody Research Group.
Shimada H; Ochiai T; Nomura F;
Cancer; 2003 Feb; 97(3):682-9. PubMed ID: 12548611
[TBL] [Abstract][Full Text] [Related]
17. Detection of prostate-specific antigen coupled to immunoglobulin M in prostate cancer patients.
Beneduce L; Prayer-Galetti T; Giustinian AM; Gallotta A; Betto G; Pagano F; Fassina G
Cancer Detect Prev; 2007; 31(5):402-7. PubMed ID: 18035503
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of the diagnostic value of serum tumor markers, and fecal k-ras and p53 gene mutations for pancreatic cancer.
Wu X; Lu XH; Xu T; Qian JM; Zhao P; Guo XZ; Yang XO; Jiang WJ
Chin J Dig Dis; 2006; 7(3):170-4. PubMed ID: 16808798
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of anticyclin B1 serum antibody as a diagnostic and prognostic biomarker for lung cancer.
Egloff AM; Weissfeld J; Land SR; Finn OJ
Ann N Y Acad Sci; 2005 Dec; 1062():29-40. PubMed ID: 16461786
[TBL] [Abstract][Full Text] [Related]
20. The levels of caspase-cleaved cytokeratin 18 are elevated in serum from patients with lung cancer and helpful to predict the survival.
Ulukaya E; Yilmaztepe A; Akgoz S; Linder S; Karadag M
Lung Cancer; 2007 Jun; 56(3):399-404. PubMed ID: 17316892
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
